January 29, 2015 — Mevion Medical Systems is announcing that the Mevion S250 proton therapy system at the Stephenson Cancer Center at the University of Oklahoma has completed its rigorous acceptance testing and is now entering the clinical commissioning phase. Clinical commissioning is the final step before physicians begin treating patients with the system.
“Providing an advanced proton therapy system for our patients will allow the Stephenson Cancer Center to remain in the forefront of cancer treatment,” said Ozer Algan, M.D., director of proton therapy at the Stephenson Cancer Center.
During four weeks of acceptance testing, the Mevion S250 was put through a series of demanding tests to validate that it meets precise technical and clinical performance requirements. The system was shown to meet or exceed all specifications, and its operational control has been officially transitioned to the physics and radiation oncology proton teams at the Stephenson Cancer Center.
“We look forward to treating our first patient with this innovative technology,” said Mike Samis, chairman of the University Hospitals Authority and Trust. “We are committed to clinical innovation and medical excellence, and this first-of-its-kind proton therapy system is a welcome addition to the comprehensive list of cancer services we offer our patients.”
Proton therapy targets cancer cells more precisely than traditional photon radiation treatment and results in less damage to surrounding healthy tissue and organs. Because of this, it is ideal for treating pediatric patients and adult patients with cancers in sensitive locations, such as near the brain, spine, heart and lungs.
The Mevion S250 delivers the same treatment advantages and capabilities of significantly larger and more expensive proton therapy systems but with a much smaller footprint, improved reliability, more efficient patient access, and dramatically lower capital and operational costs.
For more information: www.mevion.com
March 28, 2024 
